NeuroPace Discusses FDA Feedback on PMA Supplement for IGE Indication Expansion

NeuroPace held a conference call to discuss the status of its PMA Supplement seeking FDA approval to expand the indication for its RNS System to include patients with antiseizure medication-resistant idiopathic generalized epilepsy (IGE). The call featured CEO Joel Becker and Chief Medical Officer Dr. Martha Morrell, with CFO Patrick Williams also present. The company had issued a press release earlier that day providing an update on the regulatory process. The call included forward-looking statements regarding FDA review expectations and the company's submission strategy. This update is significant for NeuroPace as it seeks to broaden the market for its RNS neurostimulation device beyond its current approved indications.

First published Aug 4, 02:59 PM UTCUpdated Jul 29, 05:03 AM UTC1 reports · 1 sources

Editorial responsibility

Prepared by: WorldAttention Editorial Systems
Human review: No named human review is recorded for this page.
Automated steps: Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
Page status: Current automated evidence projection
Last updated: Jul 29, 05:03 AM UTCEditorial record as of Aug 4, 02:59 PM UTC

How automation and AI are used · Report a correction or rights issue

Wire timeline

Opened from WirecurrentJul 29, 05:03 AM UTC

NeuroPace Discusses FDA Feedback on PMA Supplement for IGE Indication Expansion

Coverage sources

External reporting used to assemble this Story.

NeuroPace Discusses FDA Feedback on PMA Supplement for IGE Indication ExpansionAll Articles on Seeking AlphaNeutral / independentJul 29, 05:03 AM UTC

Follow the context

FDA